It was great to speak with @LuskinMarlise of @DanaFarber at #ASH25, who discussed a Phase I study that combined venetoclax and inotuzumab ozogamicin for the treatment of R/R ALL.🩸

Click here to watch: 👉

#ALLsm #Leusm #HemOnc #ImmunoOnc #CTSM

A Phase I study of venetoclax plus inotuzumab ozogamicin for R/R ALL

Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, discusses a Phase I study (NCT05016947) that combi...

ow.ly

In a recent interview, @MattReesMD provided insight into a multicenter retrospective study assessing the safety & efficacy of BCMA-directed CAR-T in patients with systemic AL #amyloidosis & concurrent #MultipleMyeloma.

Watch it here: 👉

#MMSM #Myeloma

Evaluating the real-world safety and efficacy of BCMA-directed CAR-T in systemic AL amyloidosis

Matthew Rees, MD, St. Vincent's Hospital, Melbourne, Australia, provides insight into a multicenter retrospective study ...

ow.ly

Want to hear about a trial investigating huCART19-IL18, an IL18-armored CAR T-cell product, in patients with CLL/SLL and Richter’s transformation?💉🩸

Watch our interview from #ASH25 with Jakub Svoboda of @PennMedicine here:

👉 👈

#CLLsm #Leusm #CTSM

huCART19-IL18 in patients with CLL/SLL or RT after prior BTK inhibitor and venetoclax exposure

Jakub Svoboda, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, provides insight into a trial ...

ow.ly

We recently caught up with the lovely @mbeksac56 of @istinyeunivedu, who discussed a subgroup analysis of the DREAMM-7 & DREAMM-8 trials, evaluating outcomes with belantamab mafodotin in functional high-risk R/R #MultipleMyeloma.

Watch here: 👉

#MMSM

Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8

Meral Beksac, MD, Istinye University Ankara Liv Hospital, Ankara, Turkey, discusses a subgroup analysis of the DREAMM-...

ow.ly